Luca Galli
Pisa, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.
Journal: Expert review of anticancer therapy
Published: June 30, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.
Journal: Frontiers in immunology
Published: February 26, 2026
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.
Journal: NPJ precision oncology
Published: January 18, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.
Journal: Clinical genitourinary cancer
Published: January 14, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.
Journal: Frontiers in oncology
Published: November 25, 2025
Prevention of Transfusion-Transmitted Malaria and Chagas Disease in Non-Endemic Countries: An 8-Year Study of Seroprevalence Among Donors at Risk in Tuscany (Central Italy).
Journal: Pathogens (Basel, Switzerland)
Published: October 31, 2025
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.
Journal: Cancer immunology, immunotherapy : CII
Published: October 14, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).
Journal: European urology open science
Published: September 28, 2025
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study.
Journal: In vivo (Athens, Greece)
Published: August 09, 2025
Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification.
Journal: Therapeutic advances in urology
Published: August 05, 2025
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 12, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.
Journal: Cancer immunology, immunotherapy : CII
Published: July 05, 2025
Last Updated: 09/26/2026